[Federal Register Volume 77, Number 247 (Wednesday, December 26, 2012)]
[Notices]
[Pages 76041-76042]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-30866]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Terry S. Elton, Ph.D., The Ohio State University: Based on the 
reports of two investigations conducted by The Ohio State University 
(OSU) and additional analysis conducted by ORI in its oversight review, 
ORI found that Dr. Terry S. Elton, Professor, College of Pharmacy and 
Davis Heart and Lung Research Institute, OSU, engaged in research 
misconduct in research supported by National Heart, Lung, and Blood 
Institute (NHLBI), National Institutes of Health (NIH), grants R01 
HL048848, R01 HL084498, and P01 HL70294, National Institute of Child 
Health and Human Development (NICHD), NIH, grant R21 HD058997, National 
Institute on Aging (NIA), NIH, grant R01 AG021912, National Institute 
of Allergy and Infectious Diseases (NIAID), NIH, grant R01 AI39963, and 
National Eye Institute (NEI), NIH, grant R01 ES012241.
    ORI found that the Respondent engaged in research misconduct by 
falsifying and/or fabricating data that were included in 1 R21 
HD058997-01, 1 R21 HD058997-01A1, 1 R21 HD058997-01A2, 1 RC1 HL100298-
01, and in:
1. Kuhn, D.E., Nuovo, G.J., Terry, A.V. Jr., Martin, M.M., Malana, 
G.E., Sansom, SE., Pleister, A.P., Beck, W.D., Head, E., Feldman, D.S., 
& Elton, T.S. ``Chromosome 21-derived microRNAs provide an etiological 
basis for aberrant protein expression in human Down syndrome brains.'' 
J Biol Chem 285(2):1529-43, 2010 Jan 8.
2. Kuhn, D.E., Nuovo, G.J., Martin, M.M., Malana, G.E., Pleister, A.P., 
Jiang, J., Schmittgen, T.D., Terry, A.V. Jr., Gardiner, K., Head, E., 
Feldman, D.S., & Elton, T.S. ``Human chromosome 21-derived miRNAs are 
overexpressed in Down syndrome brains and hearts.'' Biochem Biophys Res 
Commun 370(3):473-7, 2008 Jun 6.
3. Martin, M.M., Buckenberger, J.A., Jiang, J., Malana, G.E., Knoell, 
D.L., Feldman, D.S., & Elton, T.S. ``TGF[szlig]1 stimulates human AT1 
receptor expression in lung fibroblasts by cross talk between the Smad, 
p38 MAPK, JNK, and PI3K signaling pathways.'' Am. J. Physiol. Lung 
Cell. Mol. Physiol. 293(3):L790-9, 2007 Sept. (Retracted: Am. J. 
Physiol. Lung Cell. Mol. Physiol. 302(7):L719, 2012 Apr.)
4. Martin, M.M., Buckenberger, J.A., Jiang, J., Malana, G.E., Nuovo, 
G.J., Chotani, M., Feldman, D.S., Schmittgen, T.D., & Elton, T.S. ``The 
human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates 
microRNA-155 binding.'' J Biol Chem 282(33):24262-9, 2007, Aug 17.
5. Martin, M.M., Buckenberger, J.A., Knoell, D.L., Strauch, A.R., & 
Elton, T.S. ``TGF-beta(1) regulation of human AT1 receptor mRNA splice 
variants harboring exon 2.'' Mol Cell Endocrinol 249(1-2):21-31, 2006 
Apr 25.
6. Duffy, A.A., Martin, M.M., & Elton, T.S. ``Transcriptional 
regulation of the AT1 receptor gene in immortalized human trophoblast 
cells.'' Biochim. Biophys. Acta. 1680(3):158-70, 2004 Nov 5.

[[Page 76042]]

    As a result of its investigation, OSU has recommended that all of 
the above publications be retracted.
    Specifically, ORI finds that Respondent:
     Falsified and/or fabricated Western blots in an NIH grant 
application in three submissions of the same grant application:

[rtrif] Figures 4, 7, 11C: 1 R21 HD058997-01
[rtrif] Figures 7B, 7E, 8B: 1 R21 HD058997-01A1
[rtrif] Figures 3C, 3F, 6C: 1 R21 HD058997-01A2
and false Western blots were also included in Figure 6 in grant 
application 1 RC1 HL100298-01.

     Falsified and/or fabricated Western blots in eighteen (18) 
figures and in six (6) published papers. Specifically false and/or 
fabricated images were included in:

[rtrif] Figures 2C, 2D, 2F, 3C, 3E, 4G, 5C, 5F: J Biol Chem 
285(2):1529-43, 2010 Jan 8
[rtrif] Figures 3B, 3C, 3F, 3H, 3I, 3J: Biochem Biophys Res Commun 
370(3):473-7, 2008 Jun 6
[rtrif] Figures 2, 3, 4B, 5B, 6, 7B, 8A, 9B: Am. J. Physiol. Lung Cell. 
Mol. Physiol. 293(3):L790-9, 2007 Sept
[rtrif] Figure 6: J Biol Chem 282(33):24262-9, 2007 Aug 17
[rtrif] Figure 6: Mol Cell Endocrinol 249(1-2):21-31, 2006 Apr 25
[rtrif] Figures 5, 6B, 7B, 9B: Biochim. Biophys. Acta 1680(3):158-70, 
2004 Nov 5.
    Dr. Elton has entered into a Voluntary Exclusion Agreement and has 
voluntarily agreed:
    (1) To exclude himself from any contracting or subcontracting with 
any agency of the United States Government and from eligibility or 
involvement in nonprocurement programs of the United States Government 
referred to as ``covered transactions'' pursuant to HHS' Implementation 
(2 CFR part 376 et seq.) of OMB Guidelines to Agencies on Govermentwide 
Debarment and Suspension, 2 CFR part 180 (collectively the ``Debarment 
Regulations'') for a period of three (3) years, beginning on November 
26, 2012;
    (2) To exclude himself voluntarily from serving in any advisory 
capacity to PHS including, but not limited to, service on any PHS 
advisory committee, board, and/or peer review committee, or as a 
consultant for a period of three (3) years, beginning on November 26, 
2012; and
    (3) To request that the following publications be retracted:

     J Biol Chem 285(2):1529-43, 2010 Jan 8
     Biochem Biophys Res Commun 370(3):473-7, 2008 Jun 6
     J Biol Chem 282(33):24262-9, 2007, Aug 17
     Mol Cell Endocrinol 249(1-2):21-31, 2006 Apr 25
     Biochim. Biophys. Acta. 1680(3):158-70, 2004 Nov 5.

FOR FURTHER INFORMATION CONTACT: Director, Office of Research 
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 
453-8200.

John E. Dahlberg,
Deputy Director, Office of Research Integrity.
[FR Doc. 2012-30866 Filed 12-21-12; 8:45 am]
BILLING CODE 4150-31-P